The short answer: a few specific effects, plenty of promises
A nootropic is a substance sought out to improve a cognitive function: alertness, attention, memory or learning. The word guarantees neither effectiveness, safety nor legality. Today, it is used to sell everything from tea to experimental powders. The category makes sense for marketing, much less so for medicine.
The best nootropic depends on the question. Caffeine supports short-term alertness. Creatine shows a small signal for memory. Bacopa remains an uncertain option, with conflicting trials. Racetams and compounds supposedly able to “repair dopamine” lack a strong enough evidence base to justify cognitive self-medication by a healthy adult.
This guide starts with ten natural options, then compares them with synthetics, psychostimulants, mushrooms and stacks. You will find the doses and populations studied in the dedicated guides. Here, the aim is to choose a direction, or decide not to buy anything.
What exactly is a nootropic?
“Nootropic”, “nootrope” and “smart drug” overlap in everyday use without referring to a single pharmacological family. A nutrient, a plant, a medicine and a psychotropic substance can all receive this label. So you need to look at the substance and its use, never just the label on the shelf.
Cognition involves several functions. Feeling awake does not prove better memory. Responding faster does not prove you make fewer mistakes. An improvement on a test in someone with cognitive impairment does not demonstrate increased ability in someone who is well rested.
Three mechanisms explain some of the research:
- Caffeine blocks adenosine receptors and reduces perceived sleepiness.
- The creatine–phosphocreatine system helps buffer cellular energy demands.
- Some products aim to modulate the stress response or neurotransmitters, but that mechanism alone does not demonstrate an everyday benefit.
The Mitochondria Marketing move is using a real biological mechanism to sell an unproven benefit. An increase in NGF in rats does not mean better memory for you. The systematic review of cognitive ingredients in healthy adults mainly finds inconsistent, imprecise and often flawed studies. The right question becomes: which function, in whom, with which extract and against which comparator?
Nootropics table: evidence, status in France and main risk
The levels below are an editorial synthesis, not a commercial ranking. A indicates strong evidence for the specifically named effect, B limited or indirect human evidence, C a preliminary or unproven signal. “Negative results” means trials do not support the claim, rather than simply a lack of studies.
The label conditionally permitted supplement does not certify any product: the species, part used, form, extract, dose and novel food rules must all comply. The Ministry of the Economy notes that a supplement cannot replace treatment. Regulatory statuses were checked as of October 12, 2026 against the official sources cited below.
| Substance | Effect studied | Evidence level | Status in France | Main risk | Dedicated guide |
|---|---|---|---|---|---|
| Caffeine | Acute alertness | A for wakefulness, not overall memory | Food or conditionally permitted supplement | Insomnia, anxiety | Coffee or tea · FR |
| Creatine monohydrate | Memory in adults with varied profiles | B, moderate certainty for memory | Conditionally permitted supplement | Digestive problems, seek advice if you have kidney disease | Creatine and the brain |
| L-theanine | Attention, alone or with caffeine | B, small effects and uncertainties | Conditionally permitted supplement | Check interactions, accompanying caffeine | L-theanine · FR |
| Bacopa monnieri | Cognitive tests after at least 12 weeks | B, conflicting results | Conditionally permitted herbal supplement | Digestive problems | Bacopa’s time frame |
| L-tyrosine | Performance under acute stress | B, low confidence | Conditionally permitted supplement | Drug interactions | Tyrosine or Alpha-GPC |
| Rhodiola rosea | Stress-related fatigue | B, indirect, no established cognitive gain | Herbal preparation, compliance must be checked | Agitation, interactions | Rhodiola · FR |
| Lion’s Mane | Cognition with mild impairment | C for healthy adults | Food or extract, compliance must be checked | Allergy, limited comparability between extracts | Lion’s Mane · FR |
| Ginkgo biloba | Memory and attention in healthy adults | Negative results in meta-analysis | Supplement or medicine depending on preparation | Bleeding and interactions | Ginkgo and memory · FR |
| Omega-3s | Prevention or cognitive support | B, indirect, not a reliable booster | Food or conditionally permitted supplement | Interactions depending on dose and treatment | DHA or EPA · FR |
| Magnesium | Cognition and sleep depending on form | C for general cognitive improvement | Supplement, specific rules depending on form | Diarrhea, accumulation with renal impairment | Threonate or bisglycinate |
| Citicoline | Memory in older adults with memory complaints | B, limited evidence | Novel food conditionally authorized | Overgeneralization of trials | Citicoline · FR |
| Alpha-GPC | Cognitive tests, varied populations | C for regular use in healthy adults | Product compliance with food regulations must be checked | Long-term uncertainty | Alpha-GPC · FR |
| Piracetam | Medical indications, cognition | Insufficient evidence as a booster for healthy people | NOOTROPYL: List II prescription medicine | Renal and bleeding risks | Piracetam · FR |
| Noopept | Vascular or traumatic cognitive disorders | C for healthy adults | Access in France not established, not an approved supplement | Uncertain safety and composition | Noopept in France |
| Bromantane | Psychophysiological parameters | C, very limited human evidence | Access in France not established, prohibited in competition | Poorly characterized human risks | Bromantane |
| Phenylpiracetam | Cognition, mainly models and patients | C for healthy adults | Prohibited in competition, possession regulated by the French Sports Code | Unknown risks and anti-doping issues | Phenylpiracetam · FR |
| Methylphenidate | Symptoms of diagnosed ADHD | A for its indication, not as a universal hack | Medicine, secure prescription required | Cardiovascular effects, sleep, misuse | Ritalin and adverse effects · FR |
| Modafinil | Wakefulness in narcolepsy | A for its indication, limited gains in healthy adults | MODIODAL: prescription medicine | Skin and psychiatric reactions | Smart drugs and risks · FR |
| Kratom | Pain, reported uses | No robust cognitive benefit | Controlled psychotropic substance, not an over-the-counter supplement | Dependence and poisoning | Kratom · FR |
| Phenibut | Anxiety, pharmacological uses | No robust cognitive benefit in healthy adults | Controlled psychotropic substance since 2020 | Dependence and severe withdrawal | Phenibut · FR |
| Psilocybin | Microdosing and cognition | No reliable gain in the cited trial | Narcotic, unrestricted use prohibited | Impaired judgment, psychiatric risk | Stamets Stack |
Natural options: the ten choices and where they actually matter
1 to 3. Caffeine, creatine and L-theanine: the most useful evidence bases for an initial sift
Caffeine: Approved for wakefulness, Conditional for work. The EFSA states that a single dose of up to 200 mg raises no safety concerns in healthy adults, but 100 mg close to bedtime can already disrupt sleep. These are safety reference points, not target doses. The matcha and coffee comparison · FR helps compare drinks without giving them different magical powers.
Creatine: Conditional for memory. A meta-analysis of 16 trials and 492 participants reports a small average effect on memory, with moderate certainty. It combines healthy adults and clinical populations. No overall improvement in cognition or executive function is established. Its 2025 corrigendum clearly distinguishes scores from processing times. You cannot translate these results into a “faster brain” in every situation. The creatine and cognition guide clarifies this boundary.
L-theanine: a small signal, not a way to cancel out coffee’s effects. The 2025 review finds modest effects on certain attention tasks, with frequent uncertainties and ties between several authors and the tea industry. A benefit of the combination over placebo does not consistently demonstrate an advantage over caffeine alone. Our theanine and ashwagandha comparison also separates calmness, attention and anxiety treatment.
4 to 6. Bacopa, tyrosine and rhodiola: context calls the shots
Bacopa: Conditional verdict, no guarantees. The earlier meta-analysis included nine trials lasting at least twelve weeks. But a 2025 trial in 101 adults aged 40 to 70 with memory or attention complaints found no advantage on its primary cognitive outcomes. Digestive complaints and headaches were more frequent. Twelve weeks is a studied duration, not a countdown to a better memory.
Tyrosine: a possibility under acute stress, not everyday fuel. The assessment of human trials considers the evidence insufficient for a firm recommendation. Preserving a function when a stressor impairs it does not mean exceeding its normal level. The tyrosine and Alpha-GPC comparison avoids confusing a precursor with a need for supplementation.
Rhodiola: stress-related fatigue, not extra IQ points. The EMA recognizes traditional use for the temporary relief of stress symptoms such as fatigue and weakness. This framework does not constitute proof of a nootropic effect or authorization for every French product. Read the rhodiola guide · FR to understand why extracts are not interchangeable.
7 to 10. Lion’s Mane, ginkgo, omega-3s and magnesium: do not confuse support with enhancement
The evidence for Lion’s Mane remains exploratory in healthy adults. Its strongest sales pitch mixes nerve growth factor with performance. The small human trials deserve a separate reading, in the mushroom section.
For ginkgo, the verdict as a booster for healthy adults is Rejected: the meta-analysis targeting this population finds no discernible effect on memory, attention or executive function. This does not settle all its medical uses. Our ginkgo analysis · FR separates these two questions.
Both omega-3s and magnesium contribute to normal physiology. That is not enough to make them effective nootropics when intake is adequate. The review of ingredients in healthy adults does not support recommending omega-3s to improve cognitive performance. The magnesium review considers the trials too limited to draw a conclusion. The comparison of magnesium forms explores the specific evidence without promising overall superiority.
If a formula presents itself as a plant-based stimulant, our audit of Sabroxy and its human evidence · FR lets you apply the same filter to another promise of better focus.
Choline and other nutrients: a mechanism does not establish an indication
Citicoline and Alpha-GPC supply choline through different pathways. The citicoline trial in 100 older adults with memory complaints reports positive results on secondary outcomes after twelve weeks, with manufacturer involvement. It does not justify prescribing it universally to students. The Alpha-GPC versus citicoline comparison · FR helps you compare populations rather than slogans.
The same discipline applies to phosphatidylserine and anti-cortisol formulas · FR and to acetyl-L-carnitine for the brain · FR: check whether the study tests the molecule alone, the blend being sold, and a population similar to you. An ingredient found in the brain is not automatically an ingredient your brain lacks.
Synthetics and racetams: more pharmacology, not necessarily more evidence
Piracetam is a medicine, not a productivity supplement. The French NOOTROPYL product information confirms a valid marketing authorization and List II prescription status. Authorization for certain indications does not demonstrate a benefit in healthy adults. The racetam guide · FR distinguishes the compounds, and the Noopept versus piracetam comparison · FR explains why “more potent” does not mean “more useful.”
Noopept is not a classic racetam. The often-cited human publication concerns cognitive disorders of vascular or traumatic origin. It does not answer the question for healthy workers. The Noopept in France dossier addresses access and unknowns, without turning an overseas seller into French authorization.
Bromantane and phenylpiracetam: I do not recommend experimenting at home. The small bromantane trial included only ten volunteers and measured EEG activity, among other things. This proves neither lasting productivity gains nor an absence of dependence. The evidence on bromantane and the phenylpiracetam dossier · FR should be read as risk analyses, not buying guides.
The 2026 prohibited list bans bromantan and fonturacetam in competition. This status is separate from food and medicines law. The French legal text on possession under the Sports Code adds another specific rule: do not generalize any one of these lists to the entire population.
Psychostimulants and ADHD: treating a disorder is not optimizing a healthy brain
Methylphenidate has a role in diagnosed ADHD. Its prescribing, indications for each medicinal product, and monitoring are regulated. The Ritaline product information specifies a secure prescription form and specialist monitoring. Our nootropics and ADHD guide · FR details why supplement trials are not equivalent.
Modafinil is authorized for narcolepsy in adults according to the MODIODAL product information. That is not authorization to study all night. In healthy adults who are not sleep-deprived, a series of meta-analyses finds small effects of certain medicines in specific domains, with limited applicability to real-world use.
No supplement should replace a prescribed treatment on its own. Saffron and ADHD · FR remain a research topic: the 2024 review included only four studies and 118 participants. Our dossier on natural alternatives to Ritaline separates support, accommodations, and treatment. For symptoms while taking medication, use the guide to Ritaline side effects and rebound · FR instead.
Mushrooms: a growth factor is not a restored memory
For Lion’s Mane, a trial in 30 people aged 50 to 80 with mild cognitive impairment found a signal on a cognitive scale after several weeks. The sample size and population severely limit extrapolation. Findings on isolated compounds do not validate every mushroom powder. The Lion’s Mane dossier · FR clarifies this distinction.
For reishi, do not turn sleep research into a promise of “corrected evening cortisol.” Our analysis of reishi, cortisol, and sleep · FR examines precisely this leap. The word “adaptogen” does not solve the lack of clinical evidence.
Psilocybin-containing mushrooms belong to another category. A controlled microdosing trial in 34 people found no improvement in creativity or cognition. Psilocybin and psilocin are on the French list of narcotic substances. The Stamets Stack and its risks therefore do not make it a natural alternative worth recommending.
Stacks: combining ingredients is not evidence of synergy
A stack is a combination of substances. To demonstrate its value, the combination must be tested at its actual doses against a relevant comparator. Adding up separate trials on five ingredients does not produce a trial of their blend.
The Pill Cupboard means accumulating supplements without knowing which one does what. The beginner focus stack · FR suggests starting with a single variable. The student study stack · FR puts sleep and learning ahead of the feeling of stimulation. The Mr. Happy Stack deserves the same filter: a story about dopamine repair does not demonstrate repair in healthy humans.
The trap may also be inside the bottle. An analysis of ten cognitive products sold in the United States detected five unauthorized drugs, with undeclared substances and inaccurate quantities. This small, targeted sample does not measure how common the problem is in France. It shows why a label is not enough.
Before buying, demand verifiable information:
- Exact identity, quantity per ingredient and per dose, with no opaque proprietary blend.
- A preparation comparable to the one studied, not just the same plant name.
- An independent, batch-specific analysis report covering identity, content, and relevant contaminants.
- Verified French regulatory status, without confusing online sales with authorization.
France: what is prescribed, controlled, or simply uncertain
A compliant supplement does not mean proven efficacy. Food regulations do not replace the evaluation of a medicine. A highly concentrated extract, a new form, or a research ingredient may be subject to specific conditions. When a product’s exact status cannot be verified, the “legal” box stays blank. I therefore do not classify Noopept or bromantane powders as freely authorized supplements.
Psychotropic and narcotic are two distinct classifications. Kratom and its alkaloids were added to the list of psychotropic substances by the order of December 23, 2019. Phenibut was added by the order of September 9, 2020. These are not ordinary supplements you can freely import. The dossiers on kratom and dependence · FR and phenibut and withdrawal · FR explain the health issues.
Psilocybin and psilocin are narcotic substances, named in Annex III of the French legal text. A small quantity or a “microdose” label does not remove that classification. Finally, banned in competition and banned from over-the-counter sale remain two different questions: anti-doping rules do not replace French product law.
Safety: precautions to check once, properly
The first mistake is treating unexplained cognitive decline with a stimulant. If it appears suddenly, progresses, or interferes with daily life, seek medical advice. After 40, just as before, sleep, medications, mood, and medical causes need to be examined. Our guide to memory loss and warning signs · FR helps you decide when to act.
The following situations require medical or pharmaceutical advice before taking a supplement:
- Pregnancy, breastfeeding, or being under 18.
- Kidney, liver, cardiovascular, neurological, or psychiatric disease.
- Treatment with an anticoagulant, antiplatelet, antidepressant, stimulant, sedative, or another medicine that could interact.
- Multiple supplements, regular use of psychoactive substances, or withdrawal symptoms.
The NCCIH notes, for example, reports of liver injury with ashwagandha and thyroid-related precautions. Natural describes an origin, not a guarantee. To check an entire formula, read our medical assessment of nootropic risks · FR.
Stop taking a new supplement if you develop new insomnia, agitation, palpitations, or a reproducible symptom, and seek advice. Chest pain, a seizure, severe confusion, difficulty breathing, or loss of consciousness warrant calling 15 or 112. If you regularly use phenibut or kratom, arrange professional care: severe phenibut withdrawal has been documented. This guide is not a withdrawal schedule.
How to decide without fooling yourself
This is not about finding your “optimal dose” by escalating. This observation framework applies only to an authorized option that is compatible with your situation, without changing any medication:
- Define a single goal, such as the number of errors on a repeatable task.
- Record your results, sleep, and usual caffeine intake for seven days, without adding a new product.
- Change only one variable, using an identified product and a duration consistent with the trials reviewed in its dedicated dossier.
- Before you start, set a reassessment date and define a concrete benefit that would justify continuing.
- Stop if your sleep worsens, an adverse effect appears or the expected benefit is not observable.
These seven days are a practical measurement choice, not a clinically validated duration. A simple before-and-after comparison remains susceptible to expectations, test practice and better nights of sleep. The notes mainly help you avoid continuing a product just because you’ve already bought the bottle.
The Verdict
To put these substances in the context of the full range of approaches, start with our biohacking guide: definition, evidence and a beginner routine. This guide remains focused on cognition and nootropics, with their specific limitations.
Main sources
Sources consulted on 12 October 2026. The available product information, evidence syntheses and summaries do not allow for an exhaustive review of every substance:
